Outlook Therapeutics receives positive CHMP opinion from European Medicines Agency for bevacizumab
March 25th 2024The positive opinion concerns authorization of bevacizumab gamma (ONS-5010/LYTENAVA), a formulation of bevacizumab for treatment of wet age-related macular degeneration (wet AMD).
Read More
AAO 2023: Do women bear a greater burden for blindness and vision loss in the United States?
November 4th 2023At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.
Read More